tumor board style presentation for oncologists, surgeons using the article explain purpose and methods of trial including clinical relevance and how we can apply to practice including pros and cons
tumor board style presentation for oncologists, surgeons using the article explain purpose and methods of trial including clinical relevance and how we can apply to practice including pros and cons
Created using ChatSlide
This project explores the use of RP1 in treating melanoma after PD-1 therapy failure. It evaluates the efficacy, safety, and applicability of combining RP1 with nivolumab, addressing the limited post-PD-1 options and the median survival of about one year. RP1, an intratumoral oncolytic immunotherapy, aims to lyse tumors, release antigens, and enhance systemic immunity by recruiting CD8+ T cells, potentially improving outcomes for patients.